Primmune Therapeutics to Present Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)

SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat viral diseases and cancers, today announced that they will present data related to PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses and Opportunistic Infections (CROI), which is being held virtually February 12–16.

Presentation details:

Title: Interim Analysis of a Phase 1 Study of PRTX007: Safety, PK and PD Response
Presenting Author: Curtis Scribner, M.D.
Presentation Number: 00474
Session Name: New Antivirals For SARS-CoV-2: Activity In Vitro and In Vivo — Poster-H02
Session Date: Tuesday, February 15
Session Time: 2:00 p.m. MST to 3:30 p.m. MST

About PRTX007

PRTX007 is Primmune’s lead TherAjuvant™, a combination of therapeutic and adjuvant mechanisms of action. PRTX007 is designed to provide immediate benefit to patients through controlled stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses. PRTX007 uniquely engages TLR7 and targeted immune cells without increasing levels of proinflammatory factors like IL-6, TNFα and IL-1β via NF-κB. TherAjuvants™ differ from other small molecule approaches in that they engage the patient’s immune system rather than acting at virally encoded targets or endogenous tumor cell proteins. PRTX007 is being rapidly advanced towards clinical trials for viral diseases and cancer.

About Primmune Therapeutics

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies as TherAjuvants™ for the treatment of viral diseases and cancers. For more information, please visit https://www.primmunerx.com/.